Company Encyclopedia
View More
name
RAILY AESMED
02135.HK
Raily Aesthetic Medicine International Holdings Limited, an investment holding company, provides aesthetic medical services in the People’s Republic of China. It operates in three segments: Aesthetic Medical Services, Consulting Services, and Aesthetic Medical Equipment Products. The company offers aesthetic surgery services, including aesthetic surgery services comprising aesthetic surgical procedures performed on various parts of the face or body; minimally invasive aesthetic services, such as aesthetic injection procedures; aesthetic dermatology services that consists of various aesthetic energy-based procedures and photoelectric items; aesthetic dental services that include orthodontics, dental implant, and dental whitening; and aesthetic medical management consulting services. It also provides aesthetic medical equipment products comprising collagen injection products, surgical implants, and aesthetic medical skincare products.
36.84 B
02135.HKMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
D
Health Care FacilitiesIndustry
Industry Ranking17/18
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-51.02%E
    • Profit Margin-39.15%E
    • Gross Margin34.44%C
  • Growth ScoreE
    • Revenue YoY-20.34%E
    • Net Profit YoY-105.11%E
    • Total Assets YoY-24.48%E
    • Net Assets YoY-40.24%E
  • Cash ScoreE
    • Cash Flow Margin-255.45%D
    • OCF YoY-20.34%E
  • Operating ScoreB
    • Turnover0.59B
  • Debt ScoreD
    • Gearing Ratio63.34%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Raily Aesthetic Medicine Delays Utilization of Proceeds Amid COVID-19 Challenges

    Raily Aesthetic Medicine International Holdings Limited (HK:2135) has announced a delay in utilizing HK$8.6 million for organic growth due to difficulties in finding suitable locations in Shanghai amid COVID-19. Additionally, HK$7.6 million from a Rights Issue remains unutilized as the company prepares for product registration. The funds are expected to be used by the end of 2025 and March 2026, respectively. The company focuses on expanding its aesthetic medical services in China and will keep stakeholders updated on progress.

    Tip Ranks·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%
    Tip Ranks·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%

    "Performance" RAILY AESMED's half-year loss expanded to 7.57 million RMB

    Raily Aesmed announced its interim results for the period ending June this year, with a revenue of RMB 84.598 million, a year-on-year decrease of 28%. The loss widened to RMB 7.57 million, compared to a loss of RMB 1.617 million in the same period last year; the loss per share was 1.36 cents. No dividend was declared

    AASTOCKS·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%
    AASTOCKS·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%

    RAILY AESMED released its interim results, with a loss attributable to shareholders of 7.57 million yuan, an increase of 368.15% year-on-year

    RAILY AESMED released its interim results for the period ending June 30, 2025, reporting revenue of RMB 84.598 million, a year-on-year decrease of 27.99%; loss attributable to equity holders of the parent company was RMB 7.57 million, a year-on-year increase of 368.15%; loss per share was 1.36 cents. Revenue from medical beauty services was approximately RMB 74.90 million, a year-on-year decrease of 9.7%, mainly due to a reduction in the number of active customers caused by intense competition

    Zhitong·
    HK
    02930
    0.00%
    HK
    02935
    0.00%
    HK
    02135
    +5.60%
    Zhitong·
    HK
    02930
    0.00%
    HK
    02935
    0.00%
    HK
    02135
    +5.60%

    Raily Aesthetic Medicine Schedules Board Meeting for Interim Results

    Raily Aesthetic Medicine International Holdings Limited (HK:2135) has scheduled a board meeting for August 29, 2025, to approve its unaudited interim results for the first half of 2025 and discuss potential dividend declarations. This meeting will impact the company's financial disclosures and shareholder returns. The company operates in the aesthetic medicine industry and is listed on the Hong Kong Stock Exchange, with a current market cap of HK$69.63M.

    Tip Ranks·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%
    Tip Ranks·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%

    RAILY AESMED and Hangzhou Bellephile terminate contract arrangement

    RAILY AESMED announced the termination of its contract arrangement with Hangzhou Bellefeel. Since 2019, RAILY AESMED has controlled Hangzhou Bellefeel through a contract and obtained its economic benefits. Due to Hangzhou Bellefeel shifting its focus to the sale of medical beauty equipment and planning to apply for a medical device business license, RAILY AESMED has terminated its medical beauty service business and canceled the relevant licenses. The board of directors decided to terminate the contract and transfer Fu Haishu's equity in Hangzhou Bellefeel to RAILY Beauty Consulting

    AASTOCKS·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%
    AASTOCKS·
    HK
    02935
    0.00%
    HK
    02930
    0.00%
    HK
    02135
    +5.60%